A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India

Autor: Kulkarni, Prasad S, Padmapriyadarsini, Chandrasekaran, Vekemans, Johan, Bavdekar, Ashish, Gupta, Madhu, Kulkarni, Praveen, Garg, B S, Gogtay, Nithya J, Tambe, Muralidhar, Lalwani, Sanjay, Singh, Kiranjit, Munshi, Renuka, Meshram, Sushant, Selvavinayagam, T S, Pandey, Krishna, Bhimarasetty, Devi Madhavi, Ramakrishnan, S R, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Vadakkedath, Rajeev, Bonhomme, Cyrille J, Thakar, Madhuri, Kurle, Swarali N, Kelly, Elizabeth J, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Bhargava, Balram, Shaligram, Umesh, Kapse, Dhananjay, Gunale, Bhagwat

Publikováno v: In eClinicalMedicine December 2021 42

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

Autor: Kulkarni PS; Serum Institute of India Pvt Ltd, Pune, India., Padmapriyadarsini C; Indian Council of Medical Research, Delhi, India., Vekemans J; Formerly of: Clinical Development, Infection, Late-stage Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bavdekar A; KEM Hospital Research Centre, Pune, India., Gupta M; Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education & Research, Chandigarh, India., Kulkarni P; Department of Community Medicine, JSS Academy of Higher Education and Research, Mysore, India., Garg BS; Department of Community Medicine and Dr Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Wardha, India., Gogtay NJ; Department of Clinical Pharmacology, Seth G S Medical College & KEM Hospital, Mumbai, India., Tambe M; Department of Community Medicine, B J Government Medical College and Sassoon General Hospitals, Pune, India., Lalwani S; Department of Pediatrics, Bharati Vidyapeeth Deemed University Medical College and Hospital, Pune, India., Singh K; Jehangir Clinical Development Centre Pvt Ltd, Pune, India., Munshi R; Department of Clinical Pharmacology, TN Medical College & BYL Nair Hospital, Mumbai, India., Meshram S; Department of Pulmonary Medicine, Government Medical College, Nagpur, India., Selvavinayagam TS; Directorate of Public Health and Preventive Medicine, Chennai, India., Pandey K; Rajendra Memorial Research Institute of Medical Sciences, Patna, India., Bhimarasetty DM; Department of Community Medicine, Andhra Medical College, Visakhapatnam, India., Ramakrishnan SR; Department of Clinical Research, Sri Ramchandra Institute of Higher Education and Research, Chennai, India., Bhamare C; Serum Institute of India Pvt Ltd, Pune, India., Dharmadhikari A; Serum Institute of India Pvt Ltd, Pune, India., Budhawant C; Biostatistics, PPD India Pvt Ltd, Mumbai, India., Bonhomme CJ; Laboratory Services, Vaccines Sciences Lab, Clinical Research, PPD, Part of Thermo Fisher Scientific, Richmond, VA, USA., Thakar M; Indian Council of Medical Research, Delhi, India., Kurle SN; Indian Council of Medical Research, Delhi, India., Kelly EJ; Formerly of: Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Gautam M; Serum Institute of India Pvt Ltd, Pune, India., Gupta N; Indian Council of Medical Research, Delhi, India., Panda S; Indian Council of Medical Research, Delhi, India., Bhargava B; Indian Council of Medical Research, Delhi, India., Poonawalla CS; Serum Institute of India Pvt Ltd, Pune, India., Shaligram U; Serum Institute of India Pvt Ltd, Pune, India., Kapse D; Serum Institute of India Pvt Ltd, Pune, India., Gunale B; Serum Institute of India Pvt Ltd, Pune, India.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2304974. Date of Electronic Publication: 2024 Mar 21.